Step into the life of John Knight, a recovering stroke patient who is now taking Pradaxa® for secondary stroke prevention. Hear John’s thoughts on why he feels confident living his active lifestyle while being on the only OAC with a widely available specific reversal agent.
Real Patient Stories & RWE | Boehringer Ingelheim
Explore real-world patients, emergencies, and evidence
To gain perspective on the use of Pradaxa® out in the real world, watch patients describe their experiences, listen to a leading cardiologist review important new data, or even interact with some data yourself.
Real Patient Cases Infographic
Two patients were taking anticoagulants for nonvalvular atrial fibrillation (NVAF). Both presented in the emergency department with aortic dissection but only one was administered Praxbind® before urgent surgery. See the sharp contrast in their courses of care and short-term outcomes.
A real-life patient case study involving a Pradaxa® patient who required urgent cholecystectomy.
A real-life patient case study involving a Pradaxa® patient who presented in the emergency department with aortic dissection.
Dr. Todd Villines reviews 2018 real-world evidence
Watch Dr. Todd Villines, from Georgetown University School of Medicine, present new real-world evidence indirectly comparing the safety and effectiveness of Pradaxa®, rivaroxaban, and apixaban using data from the largest healthcare network in the United States.
Uncovering Safety Through Real-World Evidence
There are over 33 million atrial fibrillation patients worldwide. And that number is growing. Between 2014 and 2017, over 29 robust studies in thousands of patients have compared the risk of major bleeding between dabigatran and alternative oral anticoagulants.
Connect the Curve
An interactive game featuring data from a real-world study of Pradaxa® vs rivaroxaban in patients with NVAF. The study directly compared the risk of thromboembolic stroke, intracranial haemorrhage, major extracranial bleeding events, and mortality in patients taking Pradaxa® or rivavoxaban.